Vaxcyte Inc
PCVX
Company Profile
Business description
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Contact
825 Industrial Road
Suite 300
San CarlosCA94070
USAT: +1 650 837-0111
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
414
Stocks News & Analysis
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
stocks
Chart of the Week: Where Morningstar sees attractive dividend yields in 26/27
Charts from the Australian Dividend Outlook show the sectors where they are abundant.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.80 | 11.80 | -0.13% |
| CAC 40 | 8,060.13 | 85.28 | 1.07% |
| DAX 40 | 24,597.13 | 211.35 | 0.87% |
| Dow JONES (US) | 46,601.78 | 1.20 | -0.00% |
| FTSE 100 | 9,548.87 | 65.29 | 0.69% |
| HKSE | 26,829.46 | 128.31 | -0.48% |
| NASDAQ | 23,043.38 | 255.02 | 1.12% |
| Nikkei 225 | 47,734.99 | 215.89 | -0.45% |
| NZX 50 Index | 13,610.16 | 41.68 | 0.31% |
| S&P 500 | 6,753.72 | 39.13 | 0.58% |
| S&P/ASX 200 | 8,947.60 | 10.80 | -0.12% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |